State Street Corp Cerevel Therapeutics Holdings, Inc. Transaction History

State Street Corp

$2.47 Trillion
Q4 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.96 - $42.75 $16.3 Million - $17.9 Million	-418,584 Reduced 11.86%	3,109,886 $127 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $27.7 Million - $29.3 Million	676,651 Added 23.73%	3,528,470 $149 Million
Q4 2023 Feb 14, 2024	SELL	$20.27 - $42.44 $983,419 - $2.06 Million	-48,516 Reduced 1.67%	2,851,819 $121 Million
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $2.68 Million - $4.21 Million	132,058 Added 4.77%	2,900,335 $63.3 Million
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $8.83 Million - $13.1 Million	-369,309 Reduced 11.77%	2,768,277 $88 Million
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $6.54 Million - $10.1 Million	-286,634 Reduced 8.37%	3,137,586 $76.5 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $17.9 Million - $22.5 Million	704,948 Added 25.92%	3,424,220 $108 Million
Q3 2022 Nov 15, 2022	BUY	$25.5 - $41.42 $7.77 Million - $12.6 Million	304,798 Added 12.62%	2,719,272 $76.8 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $5.2 Million - $9.38 Million	252,378 Added 11.67%	2,414,474 $63.8 Million
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $1.3 Million - $1.95 Million	-55,152 Reduced 2.49%	2,162,096 $75.7 Million
Q4 2021 Feb 14, 2022	BUY	$29.21 - $44.64 $1.62 Million - $2.48 Million	55,476 Added 2.57%	2,217,248 $71.9 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $18.1 Million - $33.1 Million	852,253 Added 65.08%	2,161,772 $63.8 Million
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $4.74 Million - $11.2 Million	377,383 Added 40.49%	1,309,519 $33.6 Million
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $11.5 Million - $16.5 Million	932,136 New	932,136 $12.8 Million

Others Institutions Holding CERE

# of Institutions

Shares Held

5.01M

Call Options Held

3.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account